KOSDAQBiotech & Pharma011040

KyungdongPharm

₩4,990▲ 0.10%2026-11-18 close
Market Cap
₩153.5B
Turnover
₩59,391,439
Volume
10K
Shares out.
30.8M
PER
11.9×
PBR
0.6×
EPS
₩421
Dividend Yield
6.01%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit recovery after CSO shift; the sales target is the test

KyungdongPharm moved from an operating loss of KRW 25 billion in 2023 to operating profit of KRW 7.67 billion in 2025, but the Q3 2026 net loss attributable to controlling shareholders and the KRW 230 billion sales target are the next tests.

  1. 1

    Sales bottomed at KRW 162.7 billion in 2023, then rose to KRW 193.9 billion in 2024 and KRW 196.3 billion in 2025, two consecutive years of growth.

  2. 2

    The operating margin rose from 1.4% in 2024 to 3.9% in 2025, which the company attributed to cost reduction and a leaner selling and administrative cost structure.

  3. 3

    Q3 2026 operating profit rose to KRW 3.88 billion, yet net loss attributable to controlling shareholders of KRW 1.81 billion moved the bottom line into the red, so the two profit lines diverged.

  4. 4

    The debt-to-equity ratio climbed from 20.6% in 2022 to 40.6% in 2025, while operating cash flow was positive at KRW 16.9 billion in 2025.

  5. 5

    Cumulative Q1–Q3 2026 sales of KRW 153.2 billion compare with a 2026 target of KRW 230 billion, and the company has set a long-term target of KRW 500 billion in annual sales for 2030.

02

Business structure

KyungdongPharm, founded in 1976 and listed on KOSDAQ, is a pharmaceutical maker focused on manufacturing and selling medicines. According to wisereport as of June 9, 2026, its pharmaceutical segment accounts for about 97% of sales, with leasing and other businesses making up the rest.

Within pharma sales, its lead line accounts for about 66% and its second line for about 27%. JobKorea's business analysis as of March 2026 shows a different split, with 27%, 22% and 20% for three product groups, so the product weights vary by data provider.

Its sales organization moved to a contract sales organization (CSO) model in 2023, and a News Way report said profitability improved clearly after that shift.

Its core lineup centers on chronic disease treatments, and Nasopra is a combination of an NSAID and a gastroprotective agent made with six-layer coating technology. Its tegoprazan generic won a patent trial on the crystal form, allowing market entry after the substance patent expires in August 2031.

In hypertension, Baldipin Plus was approved as the first triple-combination antihypertensive in Korea (reported November 17, 2025). Its sales channels are widening from internal medicine toward pediatrics, ENT and pharmacies.

In biologics, it is developing a dupilumab biosimilar and co-developing a semaglutide-based long-acting obesity injection with a Korean biotech partner. On the production side, a new plant in Yangam-myeon, Hwaseong, Gyeonggi is planned to raise capacity more than threefold.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩48.9B₩3.1B6.3%
2025Q4₩52.2B₩2.6B4.9%
2026Q1₩47.8B₩2.4B5.0%
2026Q2₩52.3B₩3.7B7.1%
2026Q3₩53.1B₩3.9B7.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩182.7B₩8.3B₩12.2B4.5%4.7%20.6%
2023₩162.7B-₩25B-₩20.7B−15.3%−9.1%28.2%
2024₩193.9B₩2.6B₩5.5B1.4%2.5%37.5%
2025₩196.3B₩7.7B₩8.5B3.9%3.7%40.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a DART-disclosed basis, sales fell from KRW 182.7 billion in 2022 to KRW 162.7 billion in 2023, a decline of 11.0%, then rose to KRW 193.9 billion in 2024, up 19.2%, and to KRW 196.3 billion in 2025, up 1.2%. 2025 was the largest sales year in the 2022–2025 period.

Operating profit went from KRW 8.31 billion in 2022 to an operating loss of KRW 25 billion in 2023, the year the sales organization moved to a CSO model, then to KRW 2.62 billion in 2024 and KRW 7.67 billion in 2025, up 192.2%. The operating margin rose from 1.4% in 2024 to 3.9% in 2025.

The company attributed this to cost-of-production improvements from manufacturing efficiency and a leaner selling and administrative cost structure as the CSO system stabilized.

Net profit attributable to controlling shareholders swung from a loss of KRW 20.7 billion in 2023 to KRW 5.47 billion in 2024 and KRW 8.53 billion in 2025, up 55.9%. Total net income including non-controlling interests, a separate figure, was KRW 8.45 billion in 2025.

Quarterly sales were KRW 47.8 billion in Q1 2026 (down 8.3% from the prior quarter), KRW 52.3 billion in Q2 (up 9.3%) and KRW 53.1 billion in Q3 (up 1.5%, or 8.6% year on year), marking two consecutive quarters of growth.

Q2 operating profit was KRW 3.7 billion, up 53.6% from the prior quarter, and Q3 operating profit was KRW 3.88 billion, up 25.6% from a year earlier. Media reports on the company's disclosures said operating profit had stayed positive for nine straight quarters since Q2 2024.

Q3 2026 net loss attributable to controlling shareholders was KRW 1.81 billion, moving in the opposite direction from operating profit, and the detailed drivers require a breakdown of the income statement.

Over the last four quarters, from Q4 2025 to Q3 2026, net profit attributable to controlling shareholders totaled KRW 11.6 billion. At the end of 2025, total liabilities were KRW 93 billion against total equity of KRW 228.9 billion, and the debt-to-equity ratio rose to 40.6%.

Operating cash flow turned positive at KRW 16.9 billion in 2025 from negative KRW 8.07 billion in 2024, while the company repaid KRW 8.6 billion of short-term borrowings and raised its cash holdings to KRW 28.4 billion.

05

Industry analysis

A government plan to revise drug pricing has raised expectations that companies with heavy generic and reimbursed-drug exposure could face profitability pressure. KyungdongPharm focuses on prescription drugs, so it must keep the improved profitability of the first half while also growing sales.

Combination drugs for hypertension, dyslipidemia and diabetes are described as growing quickly in chronic disease treatment. Combination products are valued for improving treatment effect while making dosing easier.

Biosimilars and obesity treatments are still in development, and some observers say near-term results are hard to expect. Its selection as lead institution for a national project on domestic production of essential-medicine active ingredients adds a policy dimension around supply-chain stability.

Widening its sales reach from internal medicine into pediatrics, ENT and pharmacies is part of its growth approach under the CSO model. As a synthetic-drug generic maker, its business structure differs from biologics-focused listed companies such as Samsung Biologics and Celltrion.

The company has entered a phase where cost and selling-expense improvements translate into profit, but it also needs drug-pricing clarity and sales growth at the same time.

06

Outlook

In its 2026 corporate value-up plan, the company set a target of KRW 230 billion in 2026 sales. Cumulative Q1–Q3 2026 sales were KRW 153.2 billion, so reaching the target would require about KRW 76.8 billion in Q4, based on the sum of disclosed quarterly figures.

The company said first-half sales of KRW 100.1 billion were the first time its half-year sales passed KRW 100 billion. A company official said it aims for KRW 230 billion in annual sales, citing the settled marketing agency structure and cost reduction, and expects growth to continue in the second half.

Under its PACE 2028 strategy, the company has set a long-term target of KRW 500 billion in annual sales by 2030 and plans to secure at least KRW 500 billion of production capacity through the new plant.

The new plant is described as a base for strengthening higher-value pipelines in obesity and diabetes treatments and anticancer drugs. In the pipeline, development of a dupilumab biosimilar was reported in December 2025.

In obesity treatment, the goal is to extend the dosing interval of a once-weekly semaglutide product to once a month. On shareholder returns, the company plans to keep its dividend policy and pursue share cancellation.

The next checkpoints are whether second-half sales track toward the target and whether biologics investment translates into business results.

07

Valuation

PER
11.9×
PBR
0.6×
ROE
5.2%
EPS
₩421
BPS
₩8,239
Dividend per share
₩300

The price-to-book ratio sits below 1x, and the market capitalization is below book equity. Earnings-based multiples are sensitive to quarterly swings.

Net profit attributable to controlling shareholders over the last four quarters totaled KRW 11.6 billion, but the Q3 2026 net loss shows how volatile quarterly results can be.

After the 2023 operating loss and the return to profit in 2024, earnings are still small, so earnings-based metrics alone make valuation hard to gauge. On dividends, the company disclosed a 97.6% payout ratio for 2025 and said it meets the high-dividend company criteria.

The share price relative to book value per share is on the lower side of book value, and opinions diverge: one view holds that earnings generation is weak relative to assets, while another holds that asset value exceeds earnings power.

The rise in the debt-to-equity ratio from 20.6% in 2022 to 40.6% in 2025 should also be read alongside valuation. In short, the profile is defined by a share price near book value and a high payout ratio, and earnings strength needs continued tracking through quarterly results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Structural margin recovery

The operating margin improved from -15.3% in 2023 to 3.9% in 2025. Operating profit rose for two consecutive quarters, to KRW 3.7 billion in Q2 2026 and KRW 3.88 billion in Q3 2026. The company cites cost reduction and a leaner selling cost structure as the main drivers.

Early signs of top-line growth

According to a News Way report, first-half 2026 sales of KRW 100.1 billion were the first half-year figure above KRW 100 billion in company history. Quarterly sales rose to KRW 52.3 billion in Q2 and KRW 53.1 billion in Q3 2026. The growth path continues toward the KRW 230 billion target for 2026.

Financial flexibility and pipeline

Cash holdings rose to KRW 28.4 billion at the end of 2025 from KRW 12.8 billion a year earlier, and KRW 8.6 billion of short-term borrowings was repaid. Operating cash flow turned positive at KRW 16.9 billion in 2025. A dupilumab biosimilar and a semaglutide-based obesity injection are presented as medium-term pipeline items.

09

Bear factors

Q3 2026 swing to net loss

Q3 2026 net loss attributable to controlling shareholders was KRW 1.81 billion, after positive earnings in the prior quarter. Operating profit rose to KRW 3.88 billion in the same quarter, so the operating and bottom-line results moved in opposite directions. Whether the cause is temporary or structural requires an income-statement breakdown.

Gap to the sales target

Cumulative Q1–Q3 2026 sales total KRW 153.2 billion against a KRW 230 billion target. Reaching the target implies about KRW 76.8 billion in Q4, a large step up from the KRW 53.1 billion recorded in Q3. The company expects second-half growth, but quarterly sales fell in Q1 2026.

Drug-pricing reform and rising debt

A planned revision of drug pricing has raised expectations of profitability pressure for companies with heavy generic and reimbursed-drug exposure. The debt-to-equity ratio rose from 20.6% in 2022 to 40.6% in 2025. Continued spending on the new plant and biologics could add to the financial burden.

10

Risk factors

Policy and drug pricing

Revision of drug pricing could weigh on profitability for companies with high generic and reimbursed-drug exposure. As a prescription-drug focused company, KyungdongPharm may be affected by changes in pricing policy. Its operating margin direction could shift depending on the final content and timing of the revision.

Pipeline execution

Biosimilars and obesity treatments are still in development, and some see near-term results as difficult. Delays or clinical outcomes could affect earnings plans as the company expands into biologics. Whether medium-term R&D converts into business results is the key question.

Financial and investment burden

In December 2025 the company issued KRW 10 billion of exchangeable bonds on its treasury shares and signed a KRW 50 billion facility loan from the Korea Development Bank. The debt-to-equity ratio reached 40.6% in 2025. With the new plant and higher R&D spending under way, financing and depreciation costs could weigh on earnings.

11

What to watch next

  1. December 31, 2026 (fiscal year-end)

    Checks whether full-year 2026 sales can reach the KRW 230 billion target from cumulative Q1–Q3 sales of KRW 153.2 billion. The key question is whether Q4 sales rise well above the KRW 53.1 billion of Q3.

  2. March 31, 2027 (annual report filing deadline)

    The 2026 annual report will confirm full-year net profit attributable to controlling shareholders and operating cash flow. It will show how the Q3 net loss feeds into the full-year result.

  3. May 15, 2027 (Q1 quarterly report filing deadline)

    Compares Q1 2027 sales and operating profit with KRW 47.8 billion and KRW 2.41 billion in Q1 2026. Checks whether operating profit stays positive and whether bottom-line results recover.

  4. After December 2026 (timing to be confirmed from government announcements)

    Tracks the implementation timing and scope of drug-pricing revisions for reimbursed products. This is a variable that could affect operating margins for a company with significant generic and reimbursed-drug exposure.

  5. At the time of the new plant completion announcement

    Confirms the completion and start-up schedule of the Yangam-myeon plant. Checks how the capacity expansion links to the long-term goal of KRW 500 billion in annual sales by 2030.

12

Overall view

KyungdongPharm returned to profit after its 2023 operating loss of KRW 25 billion, reaching operating profit of KRW 7.67 billion in 2025 and a margin of 3.9%. Operating profit rose for two consecutive quarters in Q2 and Q3 2026, and first-half sales passed KRW 100 billion for the first time in the company's history.

On the other hand, Q3 2026 brought a net loss attributable to controlling shareholders of KRW 1.81 billion, so the operating and bottom-line results diverged. On sales, reaching the KRW 230 billion target would require about KRW 76.8 billion in Q4, which makes the pace of second-half growth the key question.

Drug-pricing reform, the progress of biologics pipelines and the rise in the debt-to-equity ratio to 40.6% are variables to track alongside.

Valuation is defined by a share price near book value and a high payout ratio, and because earnings are still small, interpretations can shift significantly with quarterly results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. jobkorea.co.kr
  3. digitaltoday.co.kr
  4. news.nate.com
  5. hankyung.com
  6. newsway.co.kr
  7. m.news.nate.com
  8. saramin.co.kr
  9. newspim.com
  10. medifonews.com
  11. dailypharm.com
  12. thevc.kr
  13. medifonews.com
  14. news.nate.com
  15. m.dailypharm.com
  16. m.dailypharm.com
  17. m.dailypharm.com
  18. m.dailypharm.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis